Actavis

Supreme Court: Drugmakers’ Pay-for-Delay Deals Can Be Illegal

Posted on 06/17/2013 by | News | Comments

Bulletin Today | PoliticsDeals between brand-name drugmakers and their generic drug competitors that keep cheaper products off the market might illegally prevent competition, the U.S. Supreme Court ruled June 17. In so-called pay-for-delay deals or reverse settlements, a patent holder pays a would-be competitor not to sell a generic version of a drug for a specified period of time. The brand-name manufacturer can continue to charge monopoly prices, and the generic company is compensated for inaction. In Federal Trade Commission v. Actavis, the …